Phase I trial Quotient Code: QSC207682

Phase 1

Completed

• Conditions: The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.; Not Specified

• Registration Number: ISRCTN10750305
• Lead Sponsor: Constellation Pharmaceuticals (United States)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-11-11
• Study Completion: 2023-01-02
• Last Update Posted: 27 February 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 8

Inclusion Criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Exclusion Criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Study & Design

• Study Type: Interventional
• Study Design: Not specified